For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Tritanrix-HepB/Hiberix Kft. Group | Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age. | 0 | None | 0 | 100 | 87 | 100 | View |
| Tritanrix-HepB/Hiberix LD Group | Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age. | 0 | None | 0 | 100 | 84 | 100 | View |
| Tritanrix-HepB/Hiberix HD Group | Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age. | 0 | None | 0 | 99 | 81 | 99 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 11.1 | View |
| Redness (mm) | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 11.1 | View |
| Drowsiness | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 11.1 | View |
| Fever (Axillary) | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 11.1 | View |
| Irritability | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 11.1 | View |
| Loss of appetite | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 11.1 | View |
| Swelling (mm) | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 11.1 | View |